ClinicalTrials.gg
Status unknownNCT05181852Updated Jan 6, 2022

Study to Investigate the Pharmacodynamic Effects of IP2015 in Healthy Male Subjects Using the Intradermal Capsaicin Model

A Phase 1 interventional study of IP2015, dose 1 and IP2015, dose 2 in Pain, sponsored by Initiator Pharma. Status unknown. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-06.

Sponsored by Initiator Pharma · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a Phase I, randomised, double-blind, placebo-controlled, 4-way crossover study to investigate the PD effects, safety, tolerability and PK/PD correlation of two single oral dose levels of IP2015 compared to 300 mg pregabalin and placebo in healthy male subjects using the ID capsaicin model.

02

Conditions studied

  • Pain

Browse trials for

03

In context

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

This study's planned enrollment of 24 is below the median of 66 across 8,505 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Initiator Pharma is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male, with a skin type compatible with capsaicin measurements.
  • Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examination, concomitant medication, vital signs, 12-lead , clinical laboratory evaluations.
  • Subject must be in good general health with a skin type compatible with the measures, and without significant skin allergies, pigmentary disorders, or any active dermatological conditions that might interfere with the conduct of the study.

Exclusion criteria

Exclusion Criteria:

  • Any significant CNS, cardiac, pulmonary, metabolic, renal, hepatic (including Gilbert's syndrome), gastrointestinal (GI) or psychiatric conditions, or history of fainting or syncope or such condition that, in the opinion of the Investigator, may place the subject at an unacceptable risk as a participant in the study, may interfere with the interpretation of safety or tolerability data obtained in this study, or may interfere with the absorption, distribution, metabolism or excretion (ADME) of drugs, or with the completion of treatment according to this Protocol.
  • history of abnormal physical or mental health interfering with the study as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including [but not limited to], neurological, psychiatric, endocrine, cardiovascular, respiratory, GI, hepatic, or renal disorder).
  • Clinically relevant abnormal laboratory results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis), 12-lead and vital signs, or physical findings at Screening. In case of uncertain or questionable results, tests performed during Screening may be repeated to confirm eligibility or judged to be clinically irrelevant for healthy subjects.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    IP2015_dose 1

    Active

    Drug: IP2015, dose 1

  • Experimental
    IP2015_dose 2

    Active

    Drug: IP2015, dose 2

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Active comparator
    Pregabalin

    Comparator

    Drug: Pregabalin

Interventions

06

What researchers measure

Primary outcomes

  1. Pain related assessments of effect

    The area of hyperalgesia

    Time frame: A 6 hours time interval after dosing

Secondary outcomes

  1. Pain related assessments of effect

    Subjective rating of pain

    Time frame: A 6 hours time interval after dosing

  2. Pain related assessments of effect

    Pain VAS score of hyperalgesia

    Time frame: A 6 hours time interval after dosing

  3. Pain related assessments of effect

    Area and pain VAS score of brush-evoked allodynia

    Time frame: A 6 hours time interval after dosing

  4. Pain related assessments of effect

    Area of flare (AF)

    Time frame: A 6 hours time interval after dosing

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2022; primary completion for May 2022, 4 months later.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's planned 4 months is close to that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2021
First posted
Jan 6, 2022
StartEst.
Jan 5, 2022
Primary completionEst.
May 30, 2022
CompletionEst.
Jul 1, 2022
Last update
Jan 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05181852
Lead sponsor
Initiator Pharma
Responsible party
Sponsor
First posted
Jan 6, 2022
Start date
Jan 5, 2022 (estimated)
Primary completion
May 30, 2022 (estimated)
Completion
Jul 1, 2022 (estimated)
Last update
Jan 6, 2022

Study contacts

Mikael Thomsen
Contact
mt@initiatorpharma.com
23276134
Claus Olesen
Contact
ceo@initiatorpharma.com
61260035
Sandra Connell, MD
principal investigator · MAC UK

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pudafensine

Start the discussion